B. Riley analyst Mayank Mamtani lowered the firm’s price target on Harrow (HROW) to $65 from $69 and keeps a Buy rating on the shares following the Q4 report. The firm believes the “significant headroom” to multi-year volume growth for all three of the company’s brands remains underappreciated, particularly as Harrow’s commercial teams make progress. However, the firm acknowledges Harrow’s quarterly product business “lumpiness.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health’s Strong Financial Performance and Growth Prospects Justify Buy Rating and $57 Price Target
- Harrow Health Reports Strong 2024 Financial Performance
- Closing Bell Movers: Lululemon falls 10% on soft guidance
- Harrow reports Q4 EPS 24c, consensus 13c
- Harrow reports Q4 core EPS 40c, consensus 13c